Research Groups

Key Recent Publications

1. Navas MC, Suarez I, Carreño A, Uribe D, Rios WA, Cortes-Mancera F, Martel G, Vieco B, Lozano D, Jimenez C, Gouas D, Osorio G, Hoyos S, Restrepo JC, Correa G, Jaramillo S, Lopez R, Bravo LE, Arbelaez MP, Scoazec JY, Abedi-Ardekani B, Santella RM, Chemin I, Hainaut P (2011) Hepatitis B and Hepatitis C Infection Biomarkers and TP53 Mutations in Hepatocellular Carcinomas from Colombia. Hepat Res Treat 2011:582945

2. Patel K, Mining S, Wakhisi J, Gheit T, Tommasino M, Martel-Planche G, Hainaut P, Abedi-Ardekani B (2011) TP53 mutations, human papilloma virus DNA and inflammation markers in esophageal squamous cell carcinoma from the Rift Valley, a high-incidence area in Kenya. BMC Res Notes 4:469

3. Abedi-Ardekani B, Gouas D, Villar S, Sotoudeh M, Hainaut P (2011) TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations. Hepat Res Treat 2011(475965)

4. Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M (2012) Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop. Cell Death Differ 19(1):180-3

5. Villar S, Le Roux-Goglin E, Gouas DA, Plymoth A, Ferro G, Boniol M, Lereau M, Bah E, Hall AJ, Wild CP, Mendy M, Norder H, van der Sande M, Whittle H, Friesen MD, Groopman JD, Hainaut P (2011) Seasonal Variation in TP53 R249S-Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection. Environ Health Perspect 119(11):1635-40

6. Ognjanovic S, Olivier M, Bergemann TL, Hainaut P (2012) Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database. Cancer 118(5):1387-96

7. Marcel V, Olivier M, Mollereau B, Hainaut P, Bourdon JC (2011) First International p53 Isoforms Meeting: 'p53 isoforms through evolution: from identification to biological function'. Cell Death Differ 18(3):563-4

8. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P (2011) Recent advances in p53 research: novel functions for wild-type p53 and the importance of mutant p53 in human cancer. Cancer Gene Therapy 18(1):2-11

9. Olivier M, Taniere P (2011) Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Curr Opin Oncol 23(1):88-92

10. Anaganti S, Fernandez-Cuesta L, Langerød A, Hainaut P, Olivier M (2011) p53-dependent repression of Focal Adhesion Kinase in response to estradiol in breast cancer cell-lines. Cancer Letters 300(2):215-24

11. Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M (2011) p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int J Cancer 128:1813–1821

12. Fernández-Cuesta L, Anaganti S, Hainaut P, Olivier M (2010) Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Res Treat 125(1):35-42